BR112013025892A2 - método para tratar condições relacionadas com ifn-alfa - Google Patents
método para tratar condições relacionadas com ifn-alfaInfo
- Publication number
- BR112013025892A2 BR112013025892A2 BR112013025892A BR112013025892A BR112013025892A2 BR 112013025892 A2 BR112013025892 A2 BR 112013025892A2 BR 112013025892 A BR112013025892 A BR 112013025892A BR 112013025892 A BR112013025892 A BR 112013025892A BR 112013025892 A2 BR112013025892 A2 BR 112013025892A2
- Authority
- BR
- Brazil
- Prior art keywords
- ifn
- related conditions
- alpha related
- treating
- treating ifn
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20031—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
Abstract
método para tratar condições relacionadas com ifn-alfa a presente invenção refere-se a um produto imunogênico, compreendendo ifn<244> acoplado a uma molécula de proteína carreadora, que é capaz de induzir anticorpos anti-ifn<244> in vivo e seu uso para tratar condições relacionadas com ifn>244>.
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161472854P | 2011-04-07 | 2011-04-07 | |
EP11305408.4 | 2011-04-07 | ||
US61/472,854 | 2011-04-07 | ||
EP11305408A EP2508197A1 (en) | 2011-04-07 | 2011-04-07 | Method for treating IFNalpha related conditions |
EP11188125.6 | 2011-11-07 | ||
EP11188125 | 2011-11-07 | ||
PCT/EP2012/056238 WO2012136739A1 (en) | 2011-04-07 | 2012-04-04 | Method for treating ifnalpha related conditions |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112013025892A2 true BR112013025892A2 (pt) | 2016-09-06 |
BR112013025892B1 BR112013025892B1 (pt) | 2021-01-19 |
Family
ID=46968636
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013025892-6A BR112013025892B1 (pt) | 2011-04-07 | 2012-04-04 | produto imunogênico, forma de dosagem unitária, dispositivo médico e kit relacionados a ifna |
Country Status (16)
Country | Link |
---|---|
US (2) | US9993565B2 (pt) |
EP (2) | EP2694094B1 (pt) |
JP (2) | JP6335778B2 (pt) |
KR (1) | KR102017905B1 (pt) |
CN (1) | CN103608031B (pt) |
AU (1) | AU2012238643B2 (pt) |
BR (1) | BR112013025892B1 (pt) |
CA (1) | CA2832260C (pt) |
DK (1) | DK2694094T3 (pt) |
ES (1) | ES2644824T3 (pt) |
IL (1) | IL228744A0 (pt) |
MX (1) | MX348380B (pt) |
PL (1) | PL2694094T3 (pt) |
PT (1) | PT2694094T (pt) |
RU (1) | RU2639135C2 (pt) |
WO (1) | WO2012136739A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2644824T3 (es) * | 2011-04-07 | 2017-11-30 | Neovacs | Método para tratar afecciones relacionadas con IFNalfa |
WO2017009863A1 (en) * | 2015-07-14 | 2017-01-19 | Indian Immunologicals Limited | A scalable, low variation and efficient method for purification of diphtheria toxoid and uses thereof |
EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8205892D0 (sv) | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
SE8405493D0 (sv) | 1984-11-01 | 1984-11-01 | Bror Morein | Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel |
US4877612A (en) | 1985-05-20 | 1989-10-31 | Frank M. Berger | Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process |
ATE71303T1 (de) | 1986-01-14 | 1992-01-15 | Nederlanden Staat | Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung. |
US4806352A (en) | 1986-04-15 | 1989-02-21 | Ribi Immunochem Research Inc. | Immunological lipid emulsion adjuvant |
US6277828B1 (en) | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
FR2812813B1 (fr) | 2000-08-09 | 2004-11-26 | Neovacs | Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires |
FR2844514B1 (fr) | 2002-09-16 | 2007-10-19 | Neovacs | Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation |
FR2859725B1 (fr) * | 2003-09-16 | 2006-03-10 | Neovacs | Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine |
CN101381728A (zh) * | 2008-07-01 | 2009-03-11 | 丁国庆 | 人干扰素α-2b重组卡介苗及其构建方法和鉴定方法 |
ES2644824T3 (es) * | 2011-04-07 | 2017-11-30 | Neovacs | Método para tratar afecciones relacionadas con IFNalfa |
-
2012
- 2012-04-04 ES ES12712661.3T patent/ES2644824T3/es active Active
- 2012-04-04 EP EP12712661.3A patent/EP2694094B1/en active Active
- 2012-04-04 US US14/110,312 patent/US9993565B2/en active Active
- 2012-04-04 JP JP2014503144A patent/JP6335778B2/ja active Active
- 2012-04-04 PL PL12712661T patent/PL2694094T3/pl unknown
- 2012-04-04 KR KR1020137029500A patent/KR102017905B1/ko active IP Right Grant
- 2012-04-04 BR BR112013025892-6A patent/BR112013025892B1/pt active IP Right Grant
- 2012-04-04 CA CA2832260A patent/CA2832260C/en active Active
- 2012-04-04 CN CN201280028221.9A patent/CN103608031B/zh active Active
- 2012-04-04 MX MX2013011675A patent/MX348380B/es active IP Right Grant
- 2012-04-04 RU RU2013144441A patent/RU2639135C2/ru active
- 2012-04-04 AU AU2012238643A patent/AU2012238643B2/en active Active
- 2012-04-04 WO PCT/EP2012/056238 patent/WO2012136739A1/en active Application Filing
- 2012-04-04 DK DK12712661.3T patent/DK2694094T3/da active
- 2012-04-04 EP EP17184986.2A patent/EP3272355A1/en not_active Withdrawn
- 2012-04-04 PT PT127126613T patent/PT2694094T/pt unknown
-
2013
- 2013-10-06 IL IL228744A patent/IL228744A0/en active IP Right Grant
-
2017
- 2017-02-03 JP JP2017018973A patent/JP2017105812A/ja active Pending
-
2018
- 2018-03-26 US US15/935,344 patent/US20180207288A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180207288A1 (en) | 2018-07-26 |
KR20140053879A (ko) | 2014-05-08 |
AU2012238643A1 (en) | 2013-10-24 |
JP2017105812A (ja) | 2017-06-15 |
JP6335778B2 (ja) | 2018-05-30 |
PT2694094T (pt) | 2017-11-06 |
CN103608031B (zh) | 2016-08-17 |
JP2014510126A (ja) | 2014-04-24 |
MX348380B (es) | 2017-06-09 |
CA2832260C (en) | 2021-06-22 |
RU2639135C2 (ru) | 2017-12-19 |
WO2012136739A1 (en) | 2012-10-11 |
PL2694094T3 (pl) | 2018-01-31 |
MX2013011675A (es) | 2014-01-31 |
DK2694094T3 (da) | 2017-11-13 |
US9993565B2 (en) | 2018-06-12 |
CA2832260A1 (en) | 2012-10-11 |
IL228744A0 (en) | 2013-12-31 |
EP3272355A1 (en) | 2018-01-24 |
ES2644824T3 (es) | 2017-11-30 |
CN103608031A (zh) | 2014-02-26 |
KR102017905B1 (ko) | 2019-09-03 |
BR112013025892B1 (pt) | 2021-01-19 |
EP2694094A1 (en) | 2014-02-12 |
AU2012238643B2 (en) | 2017-04-13 |
EP2694094B1 (en) | 2017-08-16 |
RU2013144441A (ru) | 2015-05-20 |
US20140023617A1 (en) | 2014-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120398T1 (el) | Ανθρωποποιημενα αντισωματα που αναγνωριζουν αλφα-συνουκλεϊνη | |
BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
CY1120390T1 (el) | Συνθεση και μεθοδος για διαγνωση και θεραπεια ασθενειων που σχετιζονται με εκφυλισμο νευριτων | |
BR112018074463A2 (pt) | anticorpos anti-tim-3 e métodos de uso dos mesmos. | |
BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
BR112012027055A8 (pt) | agente estabilizante para proteínas farmacêuticas. | |
CL2015003801A1 (es) | Formulaciones de anticuerpos y metodos | |
CL2018000232A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
CY1119518T1 (el) | Τροποποιημενα αντιγονα φυματιωσης | |
CL2016000866A1 (es) | Forma salina de hidrocloruro para la inhibición de ezh2 | |
BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
BR112013021134A2 (pt) | moduladores e métodos de uso | |
BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
CL2018000107A1 (es) | Moléculas de anticuerpo que se unen a cd79 | |
BR112014020826A2 (pt) | moduladores e métodos de uso | |
BR112015020911A2 (pt) | anticorpo, uso de uma combinação e método de tratamento | |
CO6640254A2 (es) | Método para preparar anticuerpos con propiedades mejoradas | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
BR112015017307A2 (pt) | composições de espécies com baixa acidez e métodos para produção e uso das mesmas | |
EA201491548A1 (ru) | 2'-замещенные карбануклеозидные аналоги для противовирусного лечения | |
UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
CL2014000543A1 (es) | Compuestos derivados de imidazopiridazinas sustituidas con amino, inhibidores de la quinasa ,mknk2; metodo de preparacion; compuestos intermediarios y su uso; composicion farmaceutica; combinacion farmaceutica; y su uso para el tratamiento del cancer. | |
BR112013005116A2 (pt) | moduladores e métodos de uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/04/2012, OBSERVADAS AS CONDICOES LEGAIS. |